Last update Dec. 3, 2022
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Leuprorelin is also known as
Leuprorelin in other languages or writings:
Leuprorelin belongs to this group or family:
Write us at email@example.com
e-lactancia is a resource recommended by Asociación Pro Lactancia Materna (APROLAM) of Mexico
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
A synthetic decapeptide, similar to gonadorelin, analogue of natural luteinizing hormone releasing hormone (LHRH). Indicated in in vitro fertilization treatments before stimulation with exogenous gonadotropins for ovarian stimulation. Subcutaneous administration daily for 24 to 28 days per menstrual cycle. It is also used in carcinomas of the prostate and breast, endometriosis, and uterine fibroids.
At the date of the last update we did not find any published data on its excretion in breast milk.
Its pharmacokinetic data (high molecular weight and high volume of distribution) make it unlikely that significant amounts will transfer into breastmilk.
Due to its protein nature, it is inactivated in the gastrointestinal tract (Van Leusden 1994, Fraser 1993), not being absorbed (practically zero oral bioavailability), which hinders its transfer into the infant's plasma from breastmilk, except in premature infants and the immediate neonatal period, when there may be greater intestinal permeability.
A similar LHRH analogue, buserelin is excreted in breastmilk in negligible or undetectable amounts and did not cause hormonal alterations in infants breastfed by mothers who were taking it (Dewart 1987), or alterations in lactation. (Fraser 1989)
Increased prolactin has been observed in women treated with gonadorelin analogues and gonadotropins (Cavagna 2005, Kamel 1994, Meldrum 1992), although the findings are not consistent. (Chantilis 1995)
See below the information of this related product: